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P lasmodium falciparum malaria was responsible for an estimated 584,000 (range 367,000–755,000) deaths in 2013, most of which oc-curred in young children in sub-Saharan Africa1. Although the burden 
has reduced in response to global efforts to increase the provision of prov-
en malaria interventions such as insecticide-treated bed nets and access to 
health care and treatment1, it remains high. One of the challenges in reducing 
malaria transmission is the long duration of infection in the human host, which 
in semi-immune individuals may persist for a year or more2. In particular, al-
though infection often leads to disease in naive individuals, those with suf-
ficient acquired immunity can harbour parasites — and hence be onwardly 
infectious to mosquitoes — without exhibiting symptoms3. One option for 
speeding the decline in transmission could be to target the asymptomatic 
reservoir of infection4 by providing either periodic mass-screen-and-treat 
(MSAT) programmes, focal MSAT or a reactive strategy in which individu-
als living in the vicinity of an identified clinical case are screened and treated. 
However, the extent to which such strategies are able to reduce the infectious 
reservoir will depend on the extent to which the diagnostic used to identify 
infected individuals also detects those who are onwardly infectious. Anoth-
er form of targeting could take place at the population level (for example a 
village) where mass interventions are deployed if the population prevalence 
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Mass-screen-and-treat and targeted mass-drug-administration strategies are being considered as a means to interrupt transmission 
of Plasmodium falciparum malaria. However, the effectiveness of such strategies will depend on the extent to which current and 
future diagnostics are able to detect those individuals who are infectious to mosquitoes. We estimate the relationship between par-
asite density and onward infectivity using sensitive quantitative parasite diagnostics and mosquito feeding assays from Burkina Faso. 
We find that a diagnostic with a lower detection limit of 200 parasites per microlitre would detect 55% of the infectious reservoir 
(the combined infectivity to mosquitoes of the whole population weighted by how often each individual is bitten) whereas a test 
with a limit of 20 parasites per microlitre would detect 83% and 2 parasites per microlitre would detect 95% of the infectious reser-
voir. Using mathematical models, we show that increasing the diagnostic sensitivity from 200 parasites per microlitre (equivalent to 
microscopy or current rapid diagnostic tests) to 2 parasites per microlitre would increase the number of regions where transmission 
could be interrupted with a mass-screen-and-treat programme from an entomological inoculation rate below 1 to one of up to 4. 
The higher sensitivity diagnostic could reduce the number of treatment rounds required to interrupt transmission in areas of lower 
prevalence. We predict that mass-screen-and-treat with a highly sensitive diagnostic is less effective than mass drug administration 
owing to the prophylactic protection provided to uninfected individuals by the latter approach. In low-transmission settings such as 
those in Southeast Asia, we find that a diagnostic tool with a sensitivity of 20 parasites per microlitre may be sufficient for targeted 
mass drug administration because this diagnostic is predicted to identify a similar village population prevalence compared with that 
currently detected using polymerase chain reaction if treatment levels are high and screening is conducted during the dry season. 
Along with other factors, such as coverage, choice of drug, timing of the intervention, importation of infections, and seasonality, the 
sensitivity of the diagnostic can play a part in increasing the chance of interrupting transmission.
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exceeds a given threshold. In this case, the choice of diagnostic will influence 
the accuracy of the targeting and the choice of detected prevalence threshold 
above which the intervention occurs. 
Historically, microscopy was the most commonly used diagnostic, both 
in the clinic to confirm cases, and in the field to estimate the prevalence of 
asymptomatic infection. Although detection thresholds of 4–20 parasites per 
microlitre are achievable using a Giemsa-stained thick blood film in a con-
trolled laboratory setting5, thresholds of 100–200 parasites per microlitre are 
more common in field settings6. More recently, rapid diagnostic tests (RDTs) 
have been introduced in the field. These tests detect malaria antigens, most 
commonly histidine-rich protein 2 (HRP2) and plasmodium lactate dehydro-
genase (pLDH), which are antigens produced by most, but not all, P. falciparum 
parasites7–9. These diagnostics are easier to use and more reliable than mi-
croscopy, but have similar detection thresholds10,11. The advent of highly sensi-
tive molecular methods that detect parasite DNA or RNA such as polymerase 
chain reaction (PCR)12 and quantitative nucleic acid sequence based amplifi-
cation (QT-NASBA) has highlighted that many infected individuals have para-
site densities that are too low to be detected either by microscopy or RDTs13,14. 
However, even these methods do not detect all the infections that are pres-
ent in infected human hosts12,15 and they are currently not available as rou-
tine field diagnostic tests because they require high-level laboratory facilities 
for nucleic acid extraction, amplification and detection that are unavailable 
in many resource-poor endemic settings. Even the most operationally attrac-
tive molecular diagnostic available — loop-mediated isothermal amplification 
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Figure 1 | Percentage of infected individuals and the infectious reservoir detected. a, Parasite density distributions of the three infection groups defined in the 
statistical analysis section. b, Proportion of infections detected for each infection group for a range of diagnostic thresholds between 0.001 and 107 parasites per 
microlitre. For each value of the x-axis we calculate the proportion of each density distribution (from a) that would be detected. c, The proportion of the infectious 
reservoir of the whole population that would be detected for each diagnostic threshold. This is the combined infectivity to mosquitoes of all individuals with asexual 
parasite densities above the diagnostic threshold weighted by body size. The dashed vertical lines show the three detection thresholds considered: 200, 20 and 2 
parasites per microlitre. d, Proportion of the infectious reservoir detected. Comparison of the observed data as shown in c to a simulation-based approach using 
OpenMalaria. We simulated the Burkina Faso setting using OpenMalaria to see how well the distributions of parasite density and the contribution to the infectious 
reservoir could be captured. We assumed that the seasonality followed that reported in Burkina Faso48 with 30 infectious bites per person per year in the village of 
Laye and 300 in the village of Dapélogo, and we assumed that the coverage of treatment for malaria fevers was low. The assumptions about transmission intensity 
and case management were not crucial to predictions in this range. We weighted each individual’s contribution to the infectious reservoir by their body surface 
area for both the observed data and predictions to account for differential biting rates. The simulated individuals have the same age- and village-distribution as 
the observed data. The asexual densities were measured using quanitative nucleic acid sequence based amplification (QT-NASBA) whereas OpenMalaria output 
densities were calibrated to microscopy using the standard method of counting parasite against leukocytes and converting them, assuming 8,000 leukoytes per 
microlitre49. The agreement between microscopy and QT-NASBA densities is not perfect; however, we assume for the purposes of this validation that they are similar 
because they are two imperfect methods to measure the density of infection. 
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(LAMP), which involves a simple DNA extraction procedure, isothermal am-
plification and visual examination of positivity — is currently only used in re-
search settings16. 
Two recent MSAT trials, which used RDT screening to identify infections, 
failed to lead to a sustained reduction in malaria parasite prevalence or dis-
ease incidence17,18. It has been suggested that this could be at least partly due 
to ongoing transmission from low-density infections that were undetectable 
by the RDT or by microscopy. For example, in one MSAT study in Zanzibar, 
just 0.2% of people tested positive by RDT and received an antimalarial in two 
rounds 1 month apart, whereas 2.5% and 3.8% of people in the two rounds, 
respectively, were positive by PCR. RDT, therefore, detected just 8% and 5.3% 
of PCR-positive infections in each of the rounds, respectively17. A follow-up 
study in this setting found that LAMP was able to detect 3.4 times more in-
fections than RDT19. Village-level targeted mass drug administration (MDA) 
is being trialled in the Greater Mekong subregion (Cambodia, Laos, Myanmar, 
Thailand, Vietnam and Yunnan Province in China) with a view to wider im-
plementation20. In this setting a random sample of villagers is being screened 
using a PCR to inform decisions on MDA implementation. 
To improve the impact of elimination strategies such as MSAT and target-
ed MDA, researchers are developing RDTs with improved limits of detection. 
Trying to establish the appropriate target performance specifications for these 
tests raises two questions. First, how infectious are individuals with low par-
asite densities (how much could they contribute to the infectious reservoir)? 
Second, could the use of a more-sensitive diagnostic increase the ability of an 
MSAT intervention to achieve local interruption of transmission? 
We address these questions from a population perspective using a com-
bination of data analysis and mathematical modelling. Using a data set from 
a study of the human infectious reservoir for malaria in a high endemic site in 
Burkina Faso, we estimate the contribution to the infectious reservoir of indi-
viduals with different parasite densities and hence the proportion of the infec-
tious reservoir that could be detected across a range of diagnostic sensitivity 
thresholds. We then use three well-established mathematical models of ma-
laria transmission to assess how these different diagnostic sensitivities could 
improve the prospect of malaria elimination in an African and an Asian context. 
METHODS 
Data. The data set used consists of information on 130 participants from four 
age groups (<5 years, 5–14 years, 15–30 years and >30 years) in the villages 
of Laye and Dapélogo in Burkina Faso21. Study participants provided 307 ve-
nous blood samples at the start of the wet season (n = 104), the peak of the 
wet season (n = 100) and in the subsequent dry season (n = 103). Age- and 
village-matched replacements were sought if individuals were lost or refused 
follow-up visits. Only individuals with serious acute disease, including severe 
clinical malaria, were excluded from participation. Finger prick blood samples 
were used for the preparation of microscopy slides, of which 100 microscopic 
fields were double read for asexual parasites and gametocytes. Nucleic acids 
were extracted from 100 μl venous blood samples and QT-NASBA was used 
to detect all parasite stages based on 18S ribosomal RNA and specifically to 
detect mature gametocytes based on Pfs25 messenger RNA. The sensitiv-
ity of QT-NASBA was set to 0.01–0.02 parasites per microlitre for both 18S 
rRNA and Pfs25 mRNA22. Parasite and gametocyte densities were estimated 
in relation to a standard asexual and gametocyte stage V dilution series23. 
Venous blood samples of 3 ml were fed to locally reared 4- to 5-day-old female 
Anopheles gambiae sensu stricto mosquitoes24; 7 days after feeding a mean of 
39.3 (range 14–65) fully fed mosquitoes were dissected in 1% mercurochrome 
and screened for oocysts. 
Statistical analysis. To estimate the infectious reservoir, we categorized the 
sampled individuals into four groups: clinical disease, which was defined as 
individuals with the highest asexual parasite densities (>140,000 parasites 
per microlitre); asymptomatic detectable, which was defined as individuals 
who were positive using QT-NASBA and microscopy; asymptomatic unde-
tectable, which was defined as individuals who were positive by QT-NASBA 
and negative by microscopy; and uninfected individuals who were negative by 
QT-NASBA and microscopy. We define positive QT-NASBA as all individuals 
positive for 18S because this indicates the presence of asexual parasite stages. 
For the purposes of this analysis, we make the assumption that QT-NASBA is 
the gold standard diagnostic. Of the 1,095 mosquitoes that fed on 28 individ-
uals in the group negative by QT-NASBA and microscopy, only 1 became in-
fected (<0.1% of mosquitoes, 3.5% of humans), indicating that the uninfected 
individuals have extremely low infectiousness to mosquitoes. For each of the 
other groups we calculated the mean gametocyte density of gametocytaemic 
individuals, the proportion that were gametocytaemic using QT-NASBA, the 
mean gametocyte density conditional on the presence of gametocytes and the 
proportion of fed mosquitoes infected. The contribution of each group to the 
infectious reservoir was calculated as the total percentage of mosquitoes in-
fected by each group weighted by the number of people in each group and by 
the relative body surface area (based on age) of those individuals. Non-para-
metric (Wilcoxon) tests were used to test statistical significance of differences 
in parasite densities between the groups. Differences in the proportions of ga-
metocytaemic individuals and mosquitoes infected were assessed using logis-
tic regression models using random effects to allow for repeated sampling of 
some of the same individuals in the different surveys.
In the models, for a given diagnostic detection limit, the proportion of the 
infectious reservoir that is detectable is calculated as the combined onward 
infectivity to mosquitoes of all individuals with parasite densities above the 
threshold (weighted by body surface area) divided by the infectious reservoir 
of the total population. 
Mathematical models. Three established malaria transmission models were 
used to evaluate how different diagnostic thresholds would impact on the likely 
success of MSAT strategies. The first two models (the Imperial College mod-
el and OpenMalaria, which was developed by the Swiss Tropical and Public 
Health Institute and the Liverpool School of Tropical Medicine) were used to 
explore the impact of MSAT in an African context. The third (mathematical and 
economic modelling (MAEMOD) developed by the Mahidol Oxford Tropical 
Medicine Research Unit) was used to explore the impact of targeted MDA in 
an Asian context. Full mathematical details of each of the models, the process 
of fitting to data and their validation against further field data are given in refs 4, 
25–33. We summarize how the models capture the infectious reservoir. In all 
three models, we define infectivity as the probability of an individual infecting 
a feeding mosquito, and the infectious reservoir is defined as the sum of the 
infectivity of the whole population multiplied by the probability of being bitten, 
which is based on the body surface area of the individual.
Compartment and percentage of 
total infected population
Gametocyte densities 
(parasites per microlitre) 
of gametocytaemic 
individuals (median and 
interquartile range)
Proportion of individuals 
in compartment that are 
gametocytaemic (by QT-
NASBA)
Percentage of 
mosquitoes infected 
by all the individuals in 
compartment 
Contribution to infectious 
reservoir
Clinical disease (4.4%) 290.9 (181.7, 1,169.7) 100% 23.1% 9.0%
Asymptomatic detectable (42.2%) 89.2 (15.6, 490.1) 87% 12.7% 62.3% 
Asymptomatic undetectable (53.4%) 29.8 (1.9, 128.6) 59% 3.9% 28.7%
The clinical disease group consists of the 4.4% of individuals who have the highest parasite densities. Asymptomatic detectable individuals are those that are detectable by QT-NASBA and microscopy, and the 
asymptomatic undetectable individuals are those detectable by QT-NASBA, but not microscopy.
Table 1 | Gametocyte density, prevalence and proportion of mosquitoes infected for the three infection groups: clinical disease, asymptomatic detectable infection 
and asymptomatic undetectable infection, and contribution to the infectious reservoir (total infectivity weighted by body surface area). 
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Imperial College
We used a deterministic age-structured population-level transmission model 
that tracks three infected compartments of the population — clinical disease, 
patent asymptomatic infection (identifiable by microscopy), and sub-patent 
(sub-microscopic) asymptomatic infection29. Onward infectivity to mosquitoes 
is highest in clinical disease, intermediate in patent asymptomatic infection 
and lowest in sub-patent infection parameterized by fitting to four earlier mos-
quito feeding studies29. As the model does not explicitly track parasite density, 
we adapted this structure to capture a wider range of diagnostic sensitivities by 
using results of the data analysis to define the proportion of infections that are 
detectable at a given parasite threshold within each of the infected compart-
ments. An individual’s infectivity is determined by their malaria infection status 
10 days previously, to capture lags in gametocyte production. 
OpenMalaria
We used an individual-based stochastic comprehensive model of malaria ep-
idemiology28,34. In this model, a population of individuals is updated at 5-day 
time steps with model components representing new infections, parasite den-
sities, acquired immunity, morbidity, mortality and infectivity to mosquitoes. 
The course of parasite densities over an infection in a non-immune individual 
is described using historical data from patients deliberately infected with P. 
falciparum as treatment for neurosyphilis. Immunity to asexual parasites is 
derived from a combination of cumulative exposure to both inoculations and 
parasite densities, and maternal immunity26, and acts to reduce the densities. 
The model was fitted to aggregated data from several data sets but not to lon-
gitudinal patterns of densities within individuals26. Several different variants 
of this model are available. For this study we use the base model from the 
overall ensemble34. An individual’s infectiousness to mosquitoes is related to 
a weighted sum of their recent parasite densities 10, 15 and 20 days previous-
ly, allowing time for gametocytes to develop and circulate27. The probability 
of infecting a feeding mosquito is given by the probability that at least one 
male and one female gametocyte would be taken up in the blood meal, and 
the model is fitted to the data of artificial feeding carried out on the patients 
with neurosyphilis treated using malaria therapy and then scaled using field 
data to account for the difference between infectivity in experimental and field 
conditions25,27. An individual who has recently been treated or whose infection 
ended naturally may have no asexual parasites, but continue to be infectious 
for up to 20 days. The proportion of individuals detected by a diagnostic test, 
and the corresponding contribution by these individuals to the infectious res-
ervoir, is directly recorded. 
MAEMOD
We used a deterministic model for the transmission of P. falciparum malar-
ia similar to those previously described32 with four infection classes: severe; 
clinical; asymptomatic and detectable by microscopy; and asymptomatic and 
undetectable by microscopy. Each infection class has a distribution of parasi-
taemia associated with it, which is used to estimate the sensitivity of various 
diagnostic tests. Each infection class also has an infectiousness associated 
with it based on infectivity data. We assume that treated individuals test pos-
itive for HRP2 after clearance of asexual parasitaemia for different durations, 
depending on the detection limit of the test.
Simulated scenarios. We considered two implementation scenarios: an MSAT 
programme in an African setting (Zambia), and targeted MDA in Southeast 
Asia (Cambodia). The former represents a setting in which malaria transmis-
sion is moderate (15% parasite prevalence measured by microscopy in children 
under 5 years in 2012)35, whereas the latter is an area of low prevalence (<1% 
parasite prevalence across all ages measured by microscopy in 2010)36. Three 
diagnostic detection thresholds were considered: 200, 20 and 2 parasites per 
microlitre. The highest level was chosen to reflect the diagnostic threshold for 
microscopy and widely used rapid diagnostic tests, although more modern 
RDTs may have a sensitivity closer to 40 parasites per microlitre. The lower 
thresholds were chosen to reflect log orders of difference, while remaining 
a feasible target product profile for a new diagnostic test based on current 
technologies. A diagnostic threshold of 2 parasites per microlitre is currently 
achieved by LAMP and nested PCR12.
MSAT in an African setting 
The frequency, coverage and artemisinin-based combination therapy used 
were based on the current operational strategy being implemented in Zam-
bia. A single seasonality profile was used based on average rainfall patterns 
in Zambia between 2002 and 2009 obtained from the US Climate Predic-
tion Center37. We assumed three rounds of MSAT were conducted 1 month 
apart during the dry season and repeated annually for a maximum of 8 years. 
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Figure 2 | Model predictions of the proportion of infected individuals in each class and their contribution to the infectious reservoir. Proportion of the infected 
population that have clinical disease (red), asymptomatic infection detectable by microscopy (orange) and asymptomatic infection not detectable by microscopy 
(yellow), and their contribution to the infectious reservoir for a range of entomological inoculation rates  between 1 and 400. We predicted the proportion of infected 
individuals with infections detectable by microscopy for a range of transmission intensities with the three models, assuming the common inputs: stable transmission, 
constant seasonality, little case management and no other interventions present. The ‘gametocytes only’ compartment refers to individuals with recently cleared 
asexual parasites, but persisting gametocytes.
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All treatments were assumed to be with dihydroartemisinin and piperaquine, 
which has high efficacy in clearing parasites (95%) and a duration of protec-
tion of approximately 30 days38. We assumed 80% coverage of individuals at 
each round with no correlation between those receiving the drugs between 
each round, meaning that an individual has a 99% chance of being treated at 
least once per year. The simulations were undertaken for a range of assumed 
baseline transmission levels for Zambia based on entomological inoculation 
rates (EIRs) between 0.5 and 20 infectious bites per person per year with no 
imported infections from other regions . 
The Imperial College model assumes that the proportion of each infected 
compartment that is detectable for a given diagnostic threshold is unchanged 
as prevalence decreases. In this model interruption of transmission is defined 
to have occurred once the PCR-detected prevalence for all age groups has 
been sustained below 0.0149% for 50 consecutive days in the absence of 
importation. This corresponds to a 99% probability that one or fewer people 
are infected in a population of 1,000 people39. In OpenMalaria, interruption of 
transmission is achieved when there are no infected individuals in a simula-
tion. We ran 100 OpenMalaria simulations — each with a population size of 
10,000 people — for each scenario to predict the probability of interrupting 
transmission. We did not carry out a formal model comparison. 
MDA in Southeast Asia
At present, targeted MDA is considered the most promising strategy to stop 
the spread of artemisinin-resistant P. falciparum parasites in the Greater 
Mekong subregion40. In the Southeast Asian setting, targeting populations 
at the village level is being trialled20. Villages are screened to measure their 
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Figure 3 | Example simulation of time to interrupt transmission. a, Time series 
plots from the Imperial College model showing the impact of 8 years of 
intervention that consists of three rounds of mass screen and treat (MSAT) or 
mass drug administration (MDA) a month apart during the dry season with 
dihydroartemisinin and piperaquine at a coverage of 80%. The entomological 
inoculation rate is assumed to be 2.5. The blue, yellow and grey lines show the 
impact of MSAT using a diagnostic with a sensitivity of 200, 20 and 2 parasites 
per microlitre. The green line shows the impact of MDA implemented with 
the same timing and coverage as MSAT. The dashed line shows the prevalence 
threshold at which, if prevalence remains below this line for 50 consecutive days, 
we claim that transmission is interrupted. b, Enlarged version of a showing the 
interruption of transmission prevalence threshold. The arrows show the time 
at which interruption of transmission is achieved and the colours of the arrows 
correspond to the prevalence curves. EIR, entomological inoculation rates; PCR, 
polymerase chain reaction.
Figure 4 | Predictions of interruption of transmission for mass drug 
administration (MDA) and mass screen and treat (MSAT) with three diagnostic 
detection limits. a, Number of annual rounds required to interrupt transmission 
for a range of entomological inoculation rate values between 0.5 and 9.5 
predicted by the Imperial College model. b, The probability of interrupting 
transmission by transmission intensity and diagnostic sensitivity predicted by 
OpenMalaria. We simulated scenarios for each effective transmission intensity 
of 10,000 individuals with no imported infections, no correlation in who receives 
each dose and low case-management. Because OpenMalaria is stochastic, we 
ran 100 simulations at each transmission intensity and present the proportion of 
scenarios in which transmission was interrupted. We chose one point in time to 
represent the results, after four years of MSAT. a and b assume three treatment 
rounds per year 1 month apart in the dry season. 
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prevalence and then if they are above a given threshold, they are selected for 
MDA. This is performed in the context of enhanced detection and treatment of 
clinical cases and high-coverage vector control. Currently, the diagnostic used 
is PCR. We used the MAEMOD model to investigate how using an RDT with 
a sensitivity of 200, 20 or 2 parasites per microlitre would affect the identifi-
cation of villages. Simulations were performed for a single-peaked high-trans-
mission Cambodian setting41 where a village (with a population of roughly 
1,000 individuals) can have a prevalence as high as 70%. This prevalence 
would correspond to an EIR of 3.5 per year (assuming little or no treatment of 
clinical cases) or 4.5 per year (assuming high coverage of treatment of clinical 
cases) and single-peaked seasonal transmission. The predicted prevalence in 
a village over time with the different diagnostics was used to assess the ability 
of the diagnostic to select a village for targeted MDA. 
RESULTS 
Table 1 summarizes the infection status and infectivity of the 128 participants 
who were sampled once, twice or three times over one annual transmission 
cycle in Burkina Faso. Of the 277 samples, 251 were found to be positive by 
QT-NASBA. Overall, 4% (11) of infections were considered to have clinical 
disease (associated with high parasite density), 42% (106) were considered 
to have asymptomatic detectable infections and 53% (134) were asympto-
matic and negative under microscopy, but positive by QT-NASBA (referred to 
as asymptomatic undetectable). The remaining 26 samples were negative by 
both QT-NASBA and microscopy. 
Those with clinical disease had the highest gametocyte and total para-
site densities, whereas those with asymptomatic detectable infection had ga-
metocyte and total parasite densities higher than those with asymptomatic 
undetectable infection (Table 1, Fig. 1a). The infection compartment has a sig-
nificant effect on the proportion of individuals that are gametocyte positive (P 
< 0.001). This trend in parasite density and gametocytaemia is mirrored in the 
infectivity to mosquitoes: those with clinical disease infect a higher proportion 
of mosquitoes (23%) than those with microscopically asymptomatic detect-
able infection (13%) and those with asymptomatic undetectable infection 
(4%) (P < 0.001). In this setting, individuals with asymptomatic undetectable 
(sub-microscopic) infections made up 53% of the population and contributed 
29% of the infectious reservoir of the population. 
Under all three diagnostic thresholds considered, all individuals with clin-
ical disease would be detected (Fig. 1b, 1c). At a diagnostic threshold of 200 
parasites per microlitre, 74% of the individuals with asymptomatic detecta-
ble infection would be detected. Increasing the sensitivity of the diagnostic 
to 20 or 2 parasites per microlitre increases this proportion to 88% and 92%, 
respectively. Similarly, with a sensitivity of 200 parasites per microlitre, only 
22% of individuals with asymptomatic undetectable infection would be de-
tected. This proportion increases to 49% and 71% by increasing the sensitivity 
of the diagnostic to 20 or 2 parasites per microlitre, respectively. Combining 
these groups and weighting by relative infectivity to mosquitoes, only 55% 
of the infectious reservoir is detected using a threshold of 200 parasites per 
microlitre. We estimate that a new diagnostic with a sensitivity of 20 or 2 par-
asites per microlitre would be able to detect 83% and 95% of the infectious 
reservoir, respectively.
Figure 1d shows the proportion of the infectious reservoir detected in the 
Burkina Faso setting as predicted by the OpenMalaria model (the  model based 
on parasite densities, albeit calibrated to microscopy rather than QT-NASBA 
densities, and therefore the model from which such predictions can be made). 
These generally compare well to those observed in the data (Fig. 1c,d), but 
with less variability with season than observed, and a slightly smaller contri-
bution to the infectious reservoir at low parasite densities. The detectability 
of infections in the data was generally lowest at the peak of the transmission 
season, but this pattern of seasonality was not evident in OpenMalaria.
Figure 2 shows the predicted proportion of infected individuals in each in-
fection class for a range of transmission intensities assuming no seasonality in 
transmission for the three models. In both the Imperial College and OpenMa-
laria models, these proportions are predicted to remain reasonably constant 
across a range of transmission intensities, although age-specific predictions 
show a decrease in the proportion of younger children with sub-patent infec-
tions with transmission intensity and an increase in older adults in both mod-
els (results not shown). By contrast, the MAEMOD model suggests a higher 
proportion of patent infection at high-transmission intensities. This difference 
is probably due to the data sets used for validation, with the MAEMOD model 
being calibrated for low-transmission settings. In both the Imperial College 
and MAEMOD models, at low transmission, the proportion of individuals with 
clinical malaria, patent infection and sub-patent infection, and the infectivity 
from these groups closely match those observed in the Burkina Faso data (Ta-
ble 1). The OpenMalaria model suggests a similar proportion of the population 
in the patent and sub-patent categories (assuming a sensitivity of microscopy 
close to 200 parasites per microlitre), but predicts that a greater proportion 
of the infectious reservoir comes from those with patent infection. It also pre-
dicts a lower proportion of the infectious reservoir from sub-patent infections 
under the assumption of no seasonality. However, OpenMalaria fares reason-
ably well when the scenario inputs are tailored to the high-transmission, high-
ly seasonal setting (Fig. 1d). Two of the models (Imperial College and Open-
Malaria) were used to simulate the impact of MSAT strategies in a Zambian 
setting. Figure 3 shows an example of the time to interruption of transmission 
with a pre-intervention EIR of 2.5 using the Imperial College model. Here the 
model predicts MSAT using a diagnostic test with a detection limit of 200 
parasites per microlitre would not achieve interruption of transmission, even 
after 10 years. Increasing the sensitivity of the diagnostic to 20 or 2 parasites 
per microlitre would achieve interruption of transmission after 10 and 6 years, 
respectively. The Imperial College model predicts that repeated MSAT using a 
diagnostic with a detection limit of 200 parasites per microlitre only interrupts 
transmission in areas with an EIR below 1 (Fig. 4a). Increasing the sensitivity 
to 20 or 2 parasites per microlitre interrupts transmission in areas with EIRs 
up to 2.5 and 4, respectively. Increasing the sensitivity of the diagnostic also 
reduces the number of rounds required to interrupt transmission. A similar 
pattern is predicted by the OpenMalaria model: interruption of transmission 
is rare using a diagnostic with a sensitivity of 200 parasites per microlitre at 
an EIR greater than 1 (Fig. 4b). Increasing the sensitivity to 20 or 2 parasites 
per microlitre increases the probability of interruption at an EIR of 1, and at 
a sensitivity of 2 parasites per microlitre increases the range at which inter-
ruption could occur up to an EIR of 4. Thus, in a setting with a low EIR with a 
seasonality pattern from  Zambia, both an increase to 20 or to 2 parasites per 
microlitre could improve the probability of interruption and expand the range 
of settings in which this could be feasible. However, it should be noted that 
in both models MDA is predicted to be substantially more likely to interrupt 
transmission and potentially to increase the range of transmission intensities 
at which mass treatment could interrupt transmission. 
Figure 5 shows the output from the MAEMOD model applied to a Cambo-
dian setting. Owing to the persistence of HRP2 following treatment, this mod-
el reflects the seasonal variability of an RDT in predicting prevalence because 
when treatment levels are high, there will be a higher proportion of HRP2-pos-
itive individuals with cleared infections. This will have an impact on the ability 
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Figure 5 | The predicted seasonal pattern of prevalence by polymerase chain 
reaction (PCR), microscopy and rapid diagnostic test (RDT) (with detection 
thresholds of 200, 20 and 2 parasites per microlitre) over 1 year in a high-
prevalence Cambodian setting. The results show the output from the MAEMOD 
model with high-coverage treatment of clinical cases. 
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of the test to detect villages suitable for MDA on a pre-screening. If there are 
high levels of detection and treatment of clinical malaria, the model predicts 
that a diagnostic with a sensitivity of 200, 20 or 2 parasites per microlitre will 
predict a prevalence closer to the prevalence by PCR at the beginning of the 
season (when prevalence in increasing) than at the end of the season (when 
prevalence is decreasing). In this setting a threshold of 20 parasites per micro-
litre is predicted to be as accurate as PCR at predicting population prevalence 
during the early malaria season.
DISCUSSION
The success of test-and-treat strategies to clear the infectious reservoir of 
P. falciparum malaria will depend in part on the extent to which current and 
new diagnostic tools are able to detect individuals who are infectious to 
mosquitoes. Our results from a high-endemicity setting in Burkina Faso sug-
gest that individuals with sub-microscopic infection contribute 29% to the 
infectious reservoir of the population. Given the close correlation between 
the sensitivity of RDTs and microscopy10 it is likely that a similar proportion 
of the infected population would not be detected by RDTs. Thus, even if 
every person in the population is screened and treated at each round (which 
is operationally very unlikely), just under one-third of the infectious reservoir 
of the population would remain untreated. There is clearly a need to devel-
op more sensitive diagnostic tools if MSAT strategies are to be successfully 
deployed in the field.
By stratifying the data by parasite density, we were able to relate parasite 
density thresholds to the proportion of the infectious reservoir captured. At 
a threshold of 200 parasites per microlitre, only 22% of individuals with in-
fection that is undetectable by microscopy have parasite densities measured 
with QT-NASBA above this threshold. Improving the diagnostic sensitivity 
to 20 or 2 parasites per microlitre increases the proportion of successfully 
identified infected individuals to 49% and 71%, respectively. It should be not-
ed that these results are specific to the Burkina Faso study site — an area 
with very high and very seasonal transmission. Further research is required to 
understand how the results might be modified at lower transmission, in less 
seasonal settings or in settings with declining transmission. Similarly, possible 
associations of age with the detectability and transmissibility of infections, as 
well as with exposure to mosquitoes, requires further study42.
Not all infectious individuals need to be detected and treated to reduce 
the effective reproduction number to below 1. At low endemicity, the effective 
reproduction number (that takes into account the impact of all interventions) 
will be closer to 1 and hence the proportion of infections that need to be de-
tected and treated will be lower than at higher endemicity. At a given frequen-
cy of MSAT rounds, there is therefore a critical threshold of infectivity that 
needs to be detected to reduce the reproduction number to below 1. 
Using two different transmission models applied to an African setting 
with seasonal transmission, our results demonstrate that MSAT using a diag-
nostic threshold of 200 parasites per microlitre could interrupt transmission 
at an EIR of between 0.5 and 1 if operational coverage is high and the inter-
vention is continued for 8 years. By increasing the sensitivity of the diagnostic 
tenfold this is increased to an EIR of between 0.5 and 2.5, whereas increasing 
the sensitivity 100-fold would expand this to an EIR of between 2 and 4. Large 
areas of southern and eastern Africa have EIR values below 4, indicating that 
repeated MSAT programmes with a high-sensitivity diagnostic test of the 
order of 2 parasites per microlitre could be considered as an intervention in 
these areas43. However, the EIR in Burkina Faso is much higher than 4, sug-
gesting that MSAT would not be effective even with a highly sensitive diag-
nostic test (as confirmed in a recent trial17,18). Equally, using a higher sensitivity 
diagnostic could reduce the number of treatment rounds required to interrupt 
transmission, thus reducing the operational and financial requirements and 
potentially increasing the community acceptance of the intervention. These 
results do have a number of caveats; in particular, as shown elsewhere, there 
are a number of factors (including overall coverage levels, the specific drug 
used, the correlation of coverage between rounds31 the degree of importation 
from other areas44, the size of the programme, and the seasonality, timing and 
coverage of other interventions) that can have a large impact on the success 
of MSAT and MDA programmes. Similar impacts of diagnostic sensitivity on 
the probability of elimination have been found45. 
The costs and operational challenges involved in carrying out the testing 
may prove more important than diagnostic sensitivity in determining how 
many infections can be detected and treated46. MDA may be a better option 
if it is acceptable to the local population because the additional prophylactic 
effect that is obtained by giving the drug to the whole population means that it 
is always theoretically more effective than MSAT. However, conducting multi-
ple MDA rounds may be unpopular, especially if prevalence and incidence are 
low. We estimate that in the Zambia-like transmission setting described, MSAT 
using a diagnostic with a detection limit of 2 parasites per microlitre at a cov-
erage of 80% is equally as effective as MDA at a coverage of 65% (results not 
shown). In addition, the wide-scale use of MDA has been anecdotally associat-
ed with parasite resistance47, and there are worries that it may also accelerate 
the spread of artemisinin- and piperaquine-resistant malaria parasites. MSAT 
may therefore become the preferred option if transmission cannot be interrupt-
ed with vector control alone and if diagnostics become sufficiently sensitive to 
detect the minimum fraction of infectious individuals to impact transmission. 
Targeted MDA is being considered in the Greater Mekong subregion. The 
ability to accurately target villages with high numbers of infected individuals 
is crucial. We have used the MAEMOD model to compare the prevalence pre-
dicted by PCR, microscopy and RDT of three different detection limits. The 
model predicts that a 20 parasites per microlitre detection limit is as accurate 
as PCR at predicting population prevalence during the early malaria season 
and is linked to the presence of HRP2 after successful treatment (which is 
detectable for longer periods of time for lower detection limits). This leads 
to recently treated individuals testing positive by RDT after they have cleared 
their asexual parasites. This could be considered an advantage for measur-
ing population prevalence for the purposes of triggering for MDA because 
this type of low specificity is an indication of recent infection and is therefore 
linked to the current true prevalence. This aspect can therefore be exploited 
for triggered MDA interventions, even though it would be a disadvantage for 
an MSAT intervention or for clinical malaria diagnosis that leads to the treat-
ment of uninfected patients. Focal MDA could be more acceptable than MDA 
to local communities because pre-testing confirms that the parasite is present 
in the community. It could also be more attractive to policymakers, especially 
in Southeast Asia, as it would mean fewer courses of antimalarial drugs are 
given to uninfected individuals and more heavily infected communities can be 
identified and targeted. 
QT-NASBA is the most sensitive diagnostic used in the analysis, however, 
it is unable to detect all infections or infectiousness, illustrated by the fact that 
1 out of 1,095 mosquitoes fed on blood from 28 QT-NASBA negative individ-
uals became infected. This may be due to degradation of nucleic acids that 
disproportionally affect RNA-based diagnostics3 or to a limitation in sensitiv-
ity regardless of sample handling. Gametocytaemic individuals with sub-PCR 
infection were also found in a cross-sectional survey in Tanzania using a new 
ultra-sensitive PCR technique12. These findings illustrate that the available di-
agnostics do not detect all infections that are present in populations and that 
onward malaria transmission is possible (although with a low probability) from 
apparently parasite-negative individuals. Importantly, these sensitive molec-
ular techniques are currently unfeasible for large-scale malaria interventions. 
Diagnostics in development need to strike a balance between being sensitive 
enough to detect a sufficient proportion of the asymptomatic reservoir, and 
remaining cheap, useable and having a quick turnaround of results. 
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